HDR brachytherapy boost and external radiotherapy for unfavorable prostate cancer patients

Détails

ID Serval
serval:BIB_C67F0EB63D94
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Poster: résume de manière illustrée et sur une page unique les résultats d'un projet de recherche. Les résumés de poster doivent être entrés sous "Abstract" et non "Poster".
Collection
Publications
Titre
HDR brachytherapy boost and external radiotherapy for unfavorable prostate cancer patients
Titre de la conférence
WCB 2013, World Congress of Brachytherapy
Auteur(s)
Monteiro Grillo I., Pina F., Mendoça V., Amado A., Melich-Cerveira J., Marcelino G., Marques-Vidal P.
Adresse
Barcelona, Spain, May 10-12, 2012
ISBN
0167-8140
ISSN-L
0167-8140
Statut éditorial
Publié
Date de publication
2012
Volume
103
Série
Radiotherapy and Oncology
Pages
S88-S89
Langue
anglais
Résumé
Purpose/Objective: To evaluate the outcome of prostate cancer
patients treated with a combination of HDR Brachytherapy boost
(HDR-BT) and 3D conformal external pelvic radiotherapy (EBRT) in a
dose escalation study.
Materials and Methods: 162 patients were followed between
November 2004 and December 2010 . Two different dose escalation
groups were done: group 1 (n= 92), 1 fraction HDR boost (9-10 Gy )
followed by EBRT (60 Gy in 6 weeks) - BED: 203-216 Gy and group 2
(n=70): 2 fraction HDR boost (18-19 Gy), 6 hours interval between
fractions, followed by EBRT (46 Gy in 4.5 weeks) - BED: 233.3 -247 Gy;
116 pts (71.6%) received concomitant androgen deprivation. Patients
were classified according to the MSKCC criteria into high (N=137) and
intermediate (N=25) risk. Phoenix biochemical failure definition was
used. Toxicity was scored by Radiation Morbidity Scoring Criteria
(RTOG)
Results: The mean follow-up was 41 (range 7-84) months. The 7- years
cancer-specific and overall survival was 100% an 92%, respectively.
The 7 years actuarial biochemical control rate was 89% and 100% for
group 1 and 2, respectively. One patient from group 1 and two
patients from group 2 never reached a low nadir. Two patients
developed distant metastases 12 and 16 months after the treatment.
In a multivariate Cox-regression analysis neither treatment nor risk
group (intermediate vs. high risk) were associated with increased risk
for biochemical failure. The RTOG grade 3 genitourinary early toxicity
was 1.0% and 8.5% while gastrointestinal/genitourinary late toxicity
was 7.6% and 1.4% for group 1 and 2, respectively
Conclusions: HDR BT boost followed by EBRT appears to be a safe,
feasible and effective treatment for patients with unfavorable
localized prostate cancer. This study shows a beneficial effect on
biochemical control in group 2 pts, however without statistical
significance. Higher radiation doses (BED 233.3-247 Gy) do not seem
to carry extra toxicity.
Création de la notice
12/03/2013 18:31
Dernière modification de la notice
03/03/2018 21:17
Données d'usage